PLANO, Texas, Aug. 08, 2016 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today the formation of the Nuvectra Medical Advisory Board (“MAB”). The Nuvectra MAB is composed of three renowned experts in neurostimulation therapies and pain medicine. The MAB will serve as a key strategic resource for the Company as it commercializes the Algovita® Spinal Cord Stimulation System. The MAB will help guide the development of clinical study and marketing strategies, clinician education programs, and future pipeline initiatives.

The founding members of the Nuvectra MAB include:

• Robert M. Levy, MD, PhD, will serve as Chairman of the MAB. Dr. Levy is a board-certified neurological surgeon and is a member of the Executive Board of Directors of the International Neuromodulation Society (“INS”). He has more than 25 years of experience in neurosurgery, including serving in leadership and academic positions at prestigious institutions including Northwestern University Medical School; University of Florida; and the Marcus Neuroscience Institute in Boca Raton, Florida. He is also the Editor-in-Chief of Neuromodulation: Technology at the Neural Interface, the official journal of the INS.
• Jason E. Pope, MD, is board-certified in Anesthesiology and Pain Medicine. Dr. Pope previously served as faculty at Vanderbilt University Medical Center and Cleveland Clinic. He is well published in peer-reviewed journals and has presented at national and international conferences. He is the President of Summit Pain Alliance in Santa Rosa, CA, where he has an active research group and continues to be highly engaged in national and international society work within the neuromodulation and pain space.
• W. Porter McRoberts, MD, is board-certified in Physical Medicine and Rehabilitation (“PM&R”). He is a member of the Holy Cross Hospital in Ft. Lauderdale, FL and is a thought leader amongst physicians who practice neurostimulation therapies. He has been and currently is a principal investigator in numerous clinical trials studying medical device therapies for the treatment of pain.

Dr. Levy commented, “The team at Nuvectra has developed a highly innovative neurostimulation platform that has the potential to enhance clinical results and quality of life for patients receiving spinal cord stimulation. I look forward to working with my fellow members of the Medical Advisory Board and collaborating with the Company to advance the clinical evidence of the Algovita SCS system and other promising future applications.” Dr. Pope echoed a similar sentiment, “Nuvectra offers a neurostimulation platform that may improve clinical outcomes and is well poised to be a leader in technology innovation for chronic pain patients.”

Scott Drees, Chief Executive Officer of Nuvectra, said, “We are very pleased to introduce Drs. Levy, Pope and McRoberts as the founding members of the Nuvectra Medical Advisory Board. As Chairman, Dr. Levy is uniquely positioned to lead the Medical Advisory Board given his deep experience in the industry and position as Editor-in-Chief of Neuromodulation: Technology at the Neural Interface, the official journal of International Neuromodulation Society. His experience provides him with a unique and unparalleled perspective in neuromodulation therapies. We are also fortunate to have Dr. Pope and Dr. McRoberts on the Medical Advisory Board; both are leaders in their respective fields of medicine and are actively involved in neurostimulation clinical trials. All of these highly credentialed physicians will be instrumental in educating and training the medical community about the clinical benefits of Algovita. The first objectives of the Nuvectra Medical Advisory Board will be focused on refining our post market clinical study strategies for Algovita, with the goal of initiating the patient enrollment phase of these studies in the near-future.”

About Nuvectra Corporation

Nuvectra™ is a neurostimulation company committed to helping physicians improve the lives of people with chronic neurological conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation (DBS). In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the neuroscience clinical research market. Visit the Nuvectra website atwww.nuvectramed.com.